Ferric carboxymaltose

Identification

Summary

Ferric carboxymaltose is an iron replacement therapy used to treat iron deficiency anemia in adults with intolerance or inadequate clinical response to oral iron or those who have non-dialysis dependent chronic kidney disease.

Brand Names
Injectafer
Generic Name
Ferric carboxymaltose
DrugBank Accession Number
DB08917
Background

Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.

Type
Small Molecule
Groups
Approved
Synonyms
  • Ferric carboxymaltose
  • Iron carboxymaltose
  • Iron dextri-maltose
External IDs
  • VIT 45

Pharmacology

Indication

Ferric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have non-dialysis dependent chronic kidney disease.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

When measured using positron emission tomography (PET), the red cell uptake of 59-Fe and 52-Fe from INJECTAFER ranged from 61% to 99%. In patients with iron deficiency, the red cell uptake ranged from 91% to 99%. In patients with renal anemia, the red cell uptake ranged from 61% to 84%.

Mechanism of action

Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that release iron.

Absorption

When a single dose of 100 to 1000 mg of iron was given to iron deficient patients, the maximum serum concentration (Cmax) was 37 μg/mL to 333 μg/mL. These levels were obtained 15 minutes to 1.21 hours post dose (Tmax).

Volume of distribution

3 L

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Renal elimination of iron was negligible.

Half-life

7 to 12 hours.

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The most common adverse reactions (>2%) are nausea, hypertension, flushing, hypophosphatemia, and dizziness.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Calcium PhosphateFerric carboxymaltose can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrateFerric carboxymaltose can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarbidopaFerric carboxymaltose can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
CinoxacinFerric carboxymaltose can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinFerric carboxymaltose can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Ferric carboxymaltose.
DelafloxacinFerric carboxymaltose can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DimercaprolDimercaprol may increase the nephrotoxic activities of Ferric carboxymaltose.
Dipotassium phosphateFerric carboxymaltose can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
EnoxacinFerric carboxymaltose can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Ferric cationionic91O4LML61120074-52-6VTLYFUHAOXGGBS-UHFFFAOYSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
InjectaferInjection, solution50 mg/1mLIntravenousAMERICAN REGENT, INC.2013-08-12Not applicableUS flag
InjectaferInjection, solution50 mg/1mLIntravenousAMERICAN REGENT, INC.2021-06-01Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
6897GXD6OE
CAS number
9007-72-1
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
KEGG Drug
D08920
PubChem Substance
347910386
RxNav
1433693
ChEMBL
CHEMBL2108597
Drugs.com
Drugs.com Drug Page
Wikipedia
Iron_supplement
FDA label
Download (269 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentEndothelial Dysfunction / Iron Toxicity / Renal Anemia / Stress Oxidative1
4CompletedTreatmentAnemia of Chronic Kidney Disease1
4CompletedTreatmentAnemia / Heart Failure / Iron Deficiency (ID)1
4CompletedTreatmentAnemia / Iron Deficiency (ID)2
4CompletedTreatmentAnemia / Neoplasms, Colorectal2
4CompletedTreatmentChronic Heart Failure (CHF) / Iron Deficiency (ID)1
4CompletedTreatmentFatigue1
4CompletedTreatmentHeart Failure1
4CompletedTreatmentHeart Failure / Iron Deficiency (ID)2
4CompletedTreatmentInflammatory Bowel Diseases (IBD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntravenous
Injection, solutionIntravenous50 mg/mL
Injection, solution; injection, solution, concentrateIntravenous
SolutionIntravenous500 mg
Injection, solutionIntravenous50 mg/1mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US8895612No2014-11-252027-01-08US flag
US7754702No2010-07-132027-02-13US flag
US7612109No2009-11-032024-02-05US flag
US9376505No2016-06-282023-10-20US flag
US10519252No2019-12-312023-10-20US flag

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on August 01, 2013 05:33 / Updated on February 21, 2021 18:52